GemOx regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of xxx used to treat xxx. ==Regimen== {{chemo|x|xx}} {{chemo|x|xx}}...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}}GEM-OX Regimen; Gemcitabine-Oxaliplatin Regimen; GEMOX Regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of | {{PAGENAME}} refers to a regimen consisting of [[gemcitabine]] and [[oxaliplatin]] used for the treatment of [[adenocarcinoma|biliary adenocarcinoma]], [[pancreatic cancer]], [[Hepatocellular carcinoma|hepatocellular cancer]]<ref name="pmid24748335">{{cite journal| author=Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L et al.| title=Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. | journal=Invest New Drugs | year= 2014 | volume= 32 | issue= 5 | pages= 1028-35 | pmid=24748335 | doi=10.1007/s10637-014-0100-y | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24748335 }} </ref> and [[testicular cancer]]<ref name="pmid14998855">{{cite journal| author=Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M et al.| title=Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. | journal=Ann Oncol | year= 2004 | volume= 15 | issue= 3 | pages= 493-7 | pmid=14998855 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14998855 }} </ref>. This regimen is currently being studied in a variety of other cancers. | ||
==Regimen== | ==Regimen== | ||
{{chemo| | {{chemo|Gem|Gemcitabine}} | ||
{{chemo| | {{chemo|Ox|Oxaliplatin}} | ||
==Indications== | ==Indications== | ||
*[[adenocarcinoma|Biliary adenocarcinoma]], | |||
*[[Pancreatic cancer]], | |||
*[[Hepatocellular carcinoma|Hepatocellular cancer]]<ref name="pmid24748335">{{cite journal| author=Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L et al.| title=Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. | journal=Invest New Drugs | year= 2014 | volume= 32 | issue= 5 | pages= 1028-35 | pmid=24748335 | doi=10.1007/s10637-014-0100-y | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24748335 }} </ref> | |||
*[[Testicular cancer]]<ref name="pmid14998855">{{cite journal| author=Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M et al.| title=Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. | journal=Ann Oncol | year= 2004 | volume= 15 | issue= 3 | pages= 493-7 | pmid=14998855 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14998855 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 19:13, 26 March 2015
|
WikiDoc Resources for GemOx regimen |
|
Articles |
|---|
|
Most recent articles on GemOx regimen Most cited articles on GemOx regimen |
|
Media |
|
Powerpoint slides on GemOx regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on GemOx regimen at Clinical Trials.gov Trial results on GemOx regimen Clinical Trials on GemOx regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on GemOx regimen NICE Guidance on GemOx regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on GemOx regimen Discussion groups on GemOx regimen Patient Handouts on GemOx regimen Directions to Hospitals Treating GemOx regimen Risk calculators and risk factors for GemOx regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for GemOx regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:GEM-OX Regimen; Gemcitabine-Oxaliplatin Regimen; GEMOX Regimen
Overview
GemOx regimen refers to a regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer[1] and testicular cancer[2]. This regimen is currently being studied in a variety of other cancers.
Regimen
GemGemcitabine
OxOxaliplatin
Indications
References
- ↑ 1.0 1.1 Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L; et al. (2014). "Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies". Invest New Drugs. 32 (5): 1028–35. doi:10.1007/s10637-014-0100-y. PMID 24748335.
- ↑ 2.0 2.1 Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M; et al. (2004). "Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study". Ann Oncol. 15 (3): 493–7. PMID 14998855.